NCT03590262 is a Phase 4 clinical trial of Metformin in Type 1 Diabetes Mellitus, sponsored by Shenzhen People's Hospital.

Who is sponsoring NCT03590262?

NCT03590262 is sponsored by Shenzhen People's Hospital.

What drugs are being tested in NCT03590262?

Interventions in NCT03590262: Metformin.

What condition does NCT03590262 study?

NCT03590262 studies Type 1 Diabetes Mellitus, Metformin.

Is NCT03590262 still recruiting?

NCT03590262 is currently status unknown. Last updated 20 July 2018.

Last reviewed 2018-07-20 · How we verify

NCT03590262

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Metformin as add-on Therapy on Glycemic Control and Other Outcomes in Type 1 Diabetes

Status unknown Phase 4 Last updated 20 July 2018

What this trial tests

Phase 4 trial testing Metformin in Type 1 Diabetes Mellitus in 20 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
31 March 2019

30 September 2019

Quick facts

Lead sponsor	Shenzhen People's Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 January 2018
Primary completion	31 March 2019
Estimated completion	30 September 2019
Sites	1 location across China

Drugs / interventions tested

Metformin (metformin) — full drug profile →

Conditions studied

Type 1 Diabetes Mellitus — all drugs for Type 1 Diabetes Mellitus →
Metformin — all drugs for Metformin →

Sponsor

Shenzhen People's Hospital

Who can join

Adults 18 to 60, any sex, with Type 1 Diabetes Mellitus or Metformin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim Evidence of a possible connection between gut microbiota and several physiological processes linked to type 1 diabetes is increasing. However, the effect of multistrain probiotics in people with type 1 diabetes remains unclear. This study investigated the effect of metformin as add-on therapy on glycemic control and other diabetes-related outcomes in people with type 1 diabetes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Metformin improves glycemic variability in adults with type 1 diabetes mellitus: an open-label randomized control trial.
Zhang X, Xu D, Xu P, Yang S, et al · · 2021 · cited 8× · PMID 34343108 · DOI 10.1530/ec-21-0146

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Type 1 Diabetes Mellitus

Currently open trials in the same condition.

NCT07142252 — Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus · Phase 2 · recruiting
NCT07296276 — Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM · NA · recruiting
NCT07409701 — Gamification Intervertion in Children With Type 1 Diabetes · NA · recruiting
NCT07356089 — Twiist Postmarket Surveillance Study for Type 1 Diabetes · recruiting
NCT07434154 — Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults · recruiting

Other Shenzhen People's Hospital trials

Trials by the same sponsor.

NCT07512050 — Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity · NA · not yet recruiting
NCT07366255 — Safety and Efficacy of Tripalmitoleoylglycerol in the Treatment of Dermatitis · NA · completed
NCT07366229 — Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne · Phase 2 · recruiting
NCT07266532 — Topical Lactobacillus Crispatus for Skin Barrier Dysfunction in Obesity · NA · completed
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03590262 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen People's Hospital
Last refreshed: 20 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03590262.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing